Investigating open access new approach methods (NAM) to assess biological points of departure: A case study with 4 neurotoxic pesticides.

Open access new approach methods (NAM) in the US EPA ToxCast program and NTP Integrated Chemical Environment (ICE) were used to investigate activities of four neurotoxic pesticides: endosulfan, fipronil, propyzamide and carbaryl. Concordance of in vivo regulatory points of departure (POD) adjusted for interspecies extrapolation (AdjPOD) to modelled human Administered Equivalent Dose (AEDHuman) was assessed using 3-compartment or Adult/Fetal PBTK in vitro to in vivo extrapolation. Model inputs were from Tier 1 (High throughput transcriptomics: HTTr, high throughput phenotypic profiling: HTPP) and Tier 2 (single target: ToxCast) assays. HTTr identified gene expression signatures associated with potential neurotoxicity for endosulfan, propyzamide and carbaryl in non-neuronal MCF-7 and HepaRG cells. The HTPP assay in U-2 OS cells detected potent effects on DNA endpoints for endosulfan and carbaryl, and mitochondria with fipronil (propyzamide was inactive). The most potent ToxCast assays were concordant with specific components of each chemical mode of action (MOA). Predictive adult IVIVE models produced fold differences (FD) < 10 between the AEDHuman and the measured in vivo AdjPOD. The 3-compartment model was concordant (i.e., smallest FD) for endosulfan, fipronil and carbaryl, and PBTK was concordant for propyzamide. The most potent AEDHuman predictions for each chemical showed HTTr, HTPP and ToxCast were mainly concordant with in vivo AdjPODs but assays were less concordant with MOAs. This was likely due to the cell types used for testing and/or lack of metabolic capabilities and pathways available in vivo. The Fetal PBTK model had larger FDs than adult models and was less predictive overall.

Chlorpyrifos and Δ9 Tetrahydrocannabinol exposure and effects on parameters associated with the endocannabinoid system and risk factors for obesity.

Marilyn Silva. Retired from a career in toxicology and risk assessment. Increased childhood and adult obesity are associated with chlorpyrifos (CPF), an organophosphate pesticide. Cannabis (Δ9Tetrahydrocannabinol: Δ9THC) use has increased globally with legalization. CPF applications on cannabis crops lacks federally regulated tolerances and may pose health risks through exposure during development and in adulthood. Both CPF and Δ9THC affect the endocannabinoid system (eCBS), a regulator of appetite, energy balance, and gut microbiota, which, if disrupted, increases risk for obesity and related diseases. CPF inhibits eCB metabolism and Δ9THC is a partial agonist/antagonist at the cannabinoid receptor (CB1R). Effects of each on obesogenic parameters were examined via literature search. Male rodents with CPF exposure showed increased body weights, dysbiosis, inflammation and oxidative stress, potentially associated with increased eCBs acting through the gut-microbiota-adipose-brain regulatory loop. Δ9THC generally decreased body weights via partial agonism at the CB1R, lowering levels of eCBs. Dysbiosis and/or oxidative stress associated inflammation occurred with CPF, but these parameters were not tested with Δ9THC. Database deficiencies included limited endpoints to compare between chemicals/age-groups, inter-study variables (dose ranges, dosing vehicle, rodent strain, treatment duration, etc.). CPF and Δ9THC were not tested together, but human co-chemical effects would depend on exposure ratio, subject age, exposure duration, and health status, among others. An overriding concern is that both chemicals are well-documented developmental neurotoxins in addition to their low dose effects on energy balance. A co-exposure risk assessment is warranted with increased use and lack of federal CPF regulation on cannabis.

Effects of low-dose chlorpyrifos on neurobehavior and potential mechanisms: A review of studies in rodents, zebrafish, and Caenorhabditis elegans.

OBJECTIVES: Exposure to chlorpyrifos (CPF), a neurotoxic insecticide, is implicated with adverse neurodevelopmental effects in children through noncholinergic mechanisms. METHODS: This review presents qualitative and quantitative evidence in three animal models (rodent, zebrafish, and Caenorhabditis elegans), for neurodevelopmental and behavioral effects occurring at CPF doses lower than those inhibiting acetylcholinesterase (AChE). RESULTS: CPF treatment in rodents at low noncholinergic doses during neurodevelopment showed behavioral effects, including locomotor activity, neuromotor function (NMF), cognition, anxiety, social behavior, and maternal care. Zebrafish and C. elegans, which are transparent during development, allow for detailed analysis of specific systems; further, they exhibit neurotoxic effects closely emulating those observed in mammalian pathways. Qualitative results showed concordance among rodents, zebrafish and C. elegans for adverse effects on locomotor activity, NMF, and AChE inhibition. Male rodents had greater sensitivity for effects on locomotor activity than females and exposure during the gestation day 10-14 window showed consistent increases in locomotor activity at low CPF doses (≤1.0 mg kg-1 day-1 ). Zebrafish had cognitive and anxiety deficits after CPF treatment at low doses and young adult C. elegans had reproductive dysfunction associated NMF and disruption of the serotonergic pathway. Quantitative data for all three species showed neurobehavioral effects after exposure to CPF doses approximately 2-10-fold below the threshold for AChE inhibition. CONCLUSIONS: Taken together, these findings provided a weight-of-evidence for low-dose CPF neurotoxicity and noncholinergic mechanisms. Variability in laboratories, exposure methods, tests, sex, and animal species/strain might have contributed to the inconsistent results. The detrimental CPF effects during early development are relevant to human populations.

Adverse outcome pathway of developmental neurotoxicity resulting from prenatal exposures to cannabis contaminated with organophosphate pesticide residues.

There is growing concern that increased use of medical and recreational cannabis may result in increased exposure to contaminants on the cannabis, such as pesticides. Several states are moving towards implementing robust regulation of the sales, cultivation, and manufacture of cannabis products. However, there are challenges with creating health-protective regulations in an industry that, to date, has been largely unregulated. The focus of this publication is a theoretical examination of what may happen when women are exposed pre-conceptually or during pregnancy to cannabis contaminated with pesticides. We propose an adverse outcome pathway of concomitant prenatal exposure to cannabinoids and the organophosphate pesticide chlorpyrifos by curating what we consider to be the key events at the molecular, cellular, and tissue levels that result in developmental neurotoxicity. The implications of this adverse outcome pathway underscore the need to elucidate the potential developmental neurotoxicity that may result from prenatal exposure to pesticide-contaminated cannabis.

Human health risk assessment of endosulfan: II. Dietary exposure assessment.

The California Department of Pesticide Regulation (CDPR) and the United States Environmental Protection Agency (USEPA) performed dietary exposure assessments for endosulfan in 1998 and 2002, respectively. Results of the USEPA assessment showed an increased risk for the population sub-group "Children 1-6 years" (>100% of the Population Adjusted Dose [PAD]). USEPA then required registrants to satisfy database uncertainties by performing subchronic neurotoxicity and developmental neurotoxicity studies and, based on the results, USEPA decreased the Food Quality Protection Act (FQPA, 1996) Safety Factor from 10x to 1x. Additionally, several tolerances on commodities consumed in quantity by children were cancelled in 2006. CDPR re-evaluated the dietary risk initially performed in 1998 after review of these same studies. Based on a review of the revised USEPA tolerances, decreased usage, decreased consumption, cancellations, and prior health protective margins of exposure (MOEs>100), CDPR determined that it was not necessary to redo the 1998 exposure assessment. In 2007, USEPA conducted a new human health risk assessment for endosulfan combining food+drinking water residues that characterized dietary risk as %PAD=([Exposure/PAD]x100). For all relevant USEPA population sub-groups, the %PADs were<100% (health protective benchmark).

Human health risk assessment of endosulfan. I: Toxicology and hazard identification.

Endosulfan is persistent in the environment and toxic to wildlife. Legal mandates necessitate that a risk assessments be performed for endosulfan by the California Department of Pesticide Regulation (CDPR) and the United States Environmental Protection Agency (USEPA). This hazard identification (hazard ID) compared critical no-observed effect levels (NOEL) for acute, subchronic and chronic exposure intervals between the agencies. NOELs were discussed in light of their application to numerous exposure scenarios (occupational, general population and dietary). Only the acute oral NOELs differed between CDPR (0.7 mg/kg/day) and USEPA (1.5 mg/kg/day). Pregnant rabbits were considered by CDPR to be more responsive to low gavage doses of endosulfan than non-pregnant female or male rats in the acute study selected by USEPA. NOELs for other exposure routes and durations were similar between agencies. CDPR and USEPA concurred that a Food Quality Protection Act (FQPA, 1996) Safety Factor is not needed after evaluating all studies including a Developmental Neurotoxicity study. The SF was reduced to 1x. NOELs generated from this hazard ID will be used to calculate the Margins of Exposure for all scenarios and subsequently the risk characterization for endosulfan.

An assessment of the developmental, reproductive, and neurotoxicity of endosulfan.

BACKGROUND: Endosulfan has been used for over 50 years. Although most analogs have been discontinued, endosulfan has less environmental persistence. Nevertheless, pressure groups are lobbying for a worldwide ban. The reasons are: possible rodent male reproductive toxicity, other endocrine effects and cancer; human epidemiology, and exposure studies; residues appearing in remote areas of the world, e.g., the Arctic. METHODS: The endosulfan toxicology database is described and risks of its use assessed. RESULTS: Endosulfan is an antagonist at the GABA(A) receptor Cl(-) ionophore in mammalian CNS. Rat acute toxicity is moderate, LD(50)=48 (M) or 10 mg/kg/d (F), oral gavage; 130 (M), 70 mg/kg/d (F) dermal; LC(50)=34.5 microg/L (M), 12.6 microg/L (F), inhalation. Critical NOELs for risk assessment: acute oral (gavage)=0.7 mg/kg/d (rabbit developmental); Subchronic oral (diet)=1.2 mg/kg/d (rat reproduction); Chronic oral (diet)=0.6 mg/kg/d. There were no acceptable dermal toxicity studies. The critical acute and subchronic inhalation NOELs=0.001 mg/L, chronic inhalation=0.0001 mg/L (estimated). Toxicity to rat sperm occurred at doses causing neurotoxicity. Endocrine effects, resulting from P450 oxygenase(s) induction, were reversible. Increased cancer, genotoxicity, or histopathology in rodents was not observed in any organ. Possible effects on brain biogenic amine levels were probably secondary. CONCLUSIONS: Epidemiology and rodent studies suggesting autism and male reproductive toxicity are open to other interpretations. Developmental/ reproductive toxicity or endocrine disruption occurs only at doses causing neurotoxicity. Toxicity to the fetus or young animals is not more severe than that shown by adults.